Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 4,
  • 4,
  • 1,
  • 5,
  • 3,
  • 6,
  • 2 and
  • 3
BMC Cancer201010:65

https://doi.org/10.1186/1471-2407-10-65

©  Taubert et al; licensee BioMed Central Ltd. 2010

  • Received: 14 September 2009
  • Accepted: 24 February 2010
  • Published:
Open Peer Review reports

Abstract

Background

Survivin, a member of the inhibitor of apoptosis-protein family suppresses apoptosis and regulates cell division. It is strongly overexpressed in the vast majority of cancers. We were interested if survivin detected by immunohistochemistry has prognostic relevance especially for patients of the two soft tissue sarcoma entities leiomyosarcoma and synovial sarcoma.

Methods

Tumors of leiomyosarcoma (n = 24) and synovial sarcoma patients (n = 26) were investigated for their expression of survivin by immunohistochemistry. Survivin expression was assessed in the cytoplasm and the nucleus of tumor cells using an immunoreactive scoring system (IRS).

Results

We detected a survivin expression (IRS > 2) in the cytoplasm of 20 leiomyosarcomas and 22 synovial sarcomas and in the nucleus of 12 leiomyosarcomas and 9 synovial sarcomas, respectively. There was no significant difference between leiomyosarcoma and synovial sarcoma samples in their cytoplasmic or nuclear expression of survivin. Next, all sarcoma patients were separated in four groups according to their survivin expression in the cytoplasm and in the nucleus: group 1: negative (IRS 0 to 2); group 2: weak (IRS 3 to 4); group 3: moderate (IRS 6 to 8); group 4: strong (IRS 9 to 12). In a multivariate Cox's regression hazard analysis survivin expression detected in the cytoplasm or in the nucleus was significantly associated with overall survival of patients in group 3 (RR = 5.7; P = 0.004 and RR = 5.7; P = 0.022, respectively) compared to group 2 (reference). Patients whose tumors showed both a moderate/strong expression of survivin in the cytoplasm and a moderate expression of survivin in the nucleus (in both compartments IRS ≥ 6) possessed a 24.8-fold increased risk of tumor-related death (P = 0.003) compared to patients with a weak expression of survivin both in the cytoplasm and in the nucleus.

Conclusion

Survivin protein expression in the cytoplasma and in the nucleus detected by immunohistochemistry is significantly associated with prognosis of leiomyosarcoma and synovial sarcoma patients.

Keywords

  • Soft Tissue Sarcoma
  • Leiomyosarcoma
  • Synovial Sarcoma
  • Malignant Peripheral Nerve Sheath Tumor
  • Survivin Expression

Background

Leiomyosarcoma and synovial cell sarcoma are two of the most common malignant soft tissue tumors. Despite survival rates have improved in the past two decades due to advanced treatment with primary radical surgery, along with chemotherapy and radiation, long term prognosis continues to be poor. For instance, synovial sarcoma patients with non-metastatic surgically resected disease are reported to have a 5-year overall survival and the 5-year metastasis-free survival of not more than 71% and 51%, respectively [1]. These survival rates did only tend to result in better outcomes if chemotherapy was performed; clearly underscoring the absolute need for identification of prognostic relevant factors. These factors, possibly assisting in prediction of disease specific prognosis, may help to evaluate the risk for local and systemic recurrence and allow stratifying patients to different treatment strategies.

Among those factors survivin has attracted major interest as it was shown to be strongly overexpressed in a vast majority of cancers, and it is one of the most tumor-specific human gene products [2]. Survivin belongs to two major protein families, the inhibitor of apoptosis and the chromosomal passenger families thereby playing an important role for both regulation of cell death and of cytokinesis [3–7]. Recently, survivin has been considered as putative stem cell marker (reviewed in [8]). A correlation between survivin detection and prognosis of tumor patients has been described for many different cancers (reviewed in [9]). However, there are also reports indicating survivin expression is a favourable prognostic marker (reviewed in [10]). Only a few studies investigated the correlation of survivin protein expression with prognosis in sarcomas as it has been described as prognostic marker for osteosarcomas [11–13]. Nuclear localization of survivin expression was significantly correlated with a prolonged survival but cytoplasmic staining showed no correlation with patients' outcome [11]. In contrast, in another study, survivin expression was significantly associated with the PCNA-labelling index, which was correlated with the histological grades of osteosarcoma [12]. This result rather confirms a role of survivin in inhibiting apoptosis and affecting tumor progression [13]. We investigated survivin expression on the RNA level (qRT-PCR) and on the protein level (ELISA, Western hybridization) in a group of different soft tissue sarcomas including a few leiomyosarcomas and synovial sarcomas, previously. Elevated survivin RNA and protein level were significantly correlated with a poor prognosis of STS patients [9, 14]. RNA-Expression of survivin and two other stem cell-associated genes (Hiwi, hTERT) was correlated with a 15.5-fold increased risk of tumor-related death for soft tissue sarcoma patients [15]. There are only two reports that studied survivin protein expression in soft tissue sarcomas by immunohistochemistry but without correlating results with prognosis [16, 17]. Caldas et al. could show that over 80% of primary rhabdomyosarcoma tumors expressed survivin and Tabone-Eglinger et al. found survivin protein expressed in all investigated malignant peripheral nerve sheath tumors [16, 17]. This study aimed for the first time to analyse expression of survivin protein in the soft tissue entities leiomyosarcoma and synovial sarcoma by immunohistochemistry. In addition, to evaluate the prognostic impact of survivin-expression either detected in the cytoplasm or in the nucleus for leiomyosarcoma and synovial sarcoma patients.

Methods

Patients

Twenty-four leiomyosarcoma and 26 synovial sarcoma patients were included in this study. All patients gave written informed consent (Institute of Pathology, University of Halle; Department of Surgery 1, University of Leipzig; Institute of Pathology, Charite - University Medicine, Berlin; Center for Musculoskeletal Surgery, Charité - University Medicine, Berlin). The study was approved by the Local Ethics Committee from the Charite Berlin (EA2/079/07) and the Ethics Committee from the Medizinische Fakultät MLU Halle. The research carried out on humans is in compliance with the Helsinki Declaration. Our study group included 21 males and 29 female patients. The tumors were classified according to the van Unnik grading system, and the UICC guidelines [18, 19]. An overview of clinical and patho-histological data of the leiomyosarcoma and the synovial sarcoma patients is given in Table 1.
Table 1

Clinical and immunohistochemical data for leiomyosarcoma and synovial sarcoma patients

Characteristics

Cases

Survivin cytoplasm

Survivin nucleus

IRS

 

0-2

3-4

6-8

9-12

0-2

3-4

6-8

Staining

 

negative

weak

moderate

strong

negative

weak

moderate

No.

50

8

15

19

8

29

10

11

Sex

        

   Male

21

4

6

8

3

14

4

3

   Female

29

4

9

11

5

15

6

8

Histological subtype

        

   Leiomyosarcoma

24

4

9

10

1

12

8

4

   Synovial sarcoma

26

4

6

9

7

17

2

7

Tumor grade

        

   I

5

1

1

2

1

3

1

1

   II

21

5

2

10

4

11

6

4

   III

24

9

5

7

3

15

3

6

Tumor stage

        

   stage I

5

0

1

3

1

2

2

1

   stage II

22

5

3

11

3

15

2

5

   stage III

17

2

8

5

2

9

4

4

   stage IV

6

1

3

0

2

3

2

1

Complete resection

        

   radical (R0)

38

5

11

15

7

23

7

8

   not radical (R1)

12

3

4

4

1

6

3

3

Localization

        

   extremities

33

6

10

10

7

18

7

8

   trunc wall

3

0

2

0

1

2

0

1

   head/neck

2

1

0

1

0

2

0

0

   abdomen/retro-

12

1

3

8

0

7

3

2

   peritoneum

        

Patients follow-up

        

   alive

18

2

6

7

3

10

6

2

   dead

32

6

9

12

5

19

4

9

Immunohistochemical detection

Immunohistochemical detection was performed as previously described [20, 21]. Briefly, the antibody AF886 (RD Systems; Bad Nauheim, Germany, 1:400) was applied to detect survivin protein. Stained specimens were viewed at an objective magnification of ×100 and ×200 by two investigators (HJH and CH). Expression of survivin was determined in the nucleus and in the cytoplasm by assessing semi-quantitatively the percentage of marked tumor cells and the staining intensity. The percentage of positive cells was rated as follows: 1, 1-10% positive cells; 2, 11-50%; 3, 51-80%; and 4, > 80% positive cells. Staining intensity was scored as 1, weak; 2, moderate, and 3, intensive. Scores for percentage of positive cells and scores for expression intensities were multiplied to calculate an immunoreactive score (IRS) [22]; 0-2 = no staining; 3-4 = weak staining; 6-8 = moderate staining; 9-12 = strong staining. We separated the sarcoma patients according to their cytoplasmic expression of survivin in 25% percentile groups: group 1: IRS 0 to 2 (n = 8); group 2: IRS 3 to 4 (n = 15); group 3: IRS 6 to 8 (n = 19); group 4: IRS 9 to 12 (n = 8). To investigate the possibility of an additive effect of cytoplasmic and nuclear expression of survivin on survival we arranged the patients into three groups. In group 1 are all patients (n = 6) whose tumors showed a weak staining of survivin both in the cytoplasm and in the nucleus. In group 2 (n = 35) are all remaining patients; but patients of group 3 (n = 9) with a moderate or strong survivin staining in the cytoplasm and a moderate survivin expression in the nucleus (in both compartments survivin expression showed an immunoreactive score = 6; Table 2). As negative control slides without addition of primary antibody were included for each staining.
Table 2

Multivariate Cox's regression hazard analyses

Survivin protein-level

Cytoplasm

Nucleus

 

N

RR

P

N

RR

P

Svv weak (IRS = 3-4)

15

reference

 

10

reference

 

Svv negative(IRS = 0-2)

8

4.2

0.055

29

3.1

0.110

Svv moderate (IRS = 6-8)

19

5.7

0.004

11

5.7

0.022

Svv strong (IRS = 9-12)

8

2.4

0.241

none

  

Combined Svv protein levels

      

Svv cytopl. & nucleus weak (IRS = 3-4)1

6

reference

    

Svv all other cases

35

9.4

0.024

   

Svv cytopl. & nucleus moderate+strong (IRS ≥ 6)2

9

24.8

0.003

   

Correlation of survivin expression in cytoplasm and/or nucleus with prognosis of leiomyosarcoma and synovial sarcoma patients.

Significant results are in bold face; 1Survivin expression both in cytoplasm and in nucleus weak (all IRS = 3-4); 2Survivin expression in cytoplasm moderate or strong and survivin expression in nucleus moderate (all IRS ≥ 6)

Abbreviations: Svv-survivin; IRS-immunoreactive score; cytopl.-cytoplasma

Statistical analyses

Statistical analyses were performed with the SPSS 17.0 software package (SPSS Inc., Chicago, IL). Associations between immunohistochemical stainings and clinical data were calculated with the chi2-test. Correlation of expression of survivin with survival was determined in multivariate Cox's regression hazard models (adjusted to tumor stage, tumor localization and type of tumor resection). A p-value of less than 0.05 was considered as statistically significant.

Results

Survivin expression in leiomyosarcoma and synovial sarcoma

The expression of survivin in the leiomyosarcoma specimens (n = 24) was negative in four, weak in nine, moderate in ten and strong in one cases in the cytoplasm and it was negative in 12, weak in eight, and moderate in four cases in the nucleus, respectively (Table 1; Fig.1). We detected in the synovial sarcoma samples (n = 26) a survivin expression that was negative, weak, moderate or strong in four, six, nine and seven cases in the cytoplasm and that was negative, weak or moderate in 17, two or seven cases, respectively (Table 1; Fig.1). Although, the number of more strongly stained specimens is somewhat higher for synovial sarcomas there was no significant difference in survivin expression between leiomyosarcomas and synovial sarcomas. Therefore, we combined cases of both tumor entities for further statistical analyses. However, future studies in a larger number of leiomyosarcomas and synovial sarcomas have to validate the decision to combine both sarcoma entities in statistical analysis. An association between cytoplasmic and nuclear expression of survivin as trend was found (P = 0.061; chi2-test).
Figure 1
Figure 1

Immunohistochemical detection of survivin. Detection of survivin in leiomyosarcoma in cytoplasm (A) and in cytoplasm+nuclei (B) Detection of survivin in synovial sarcoma in cytoplasm (C) and in cytoplasm+nuclei (D) (magnification 200×)

Correlation of survivin expression with clinical data and prognosis

Expressions of survivin both in the cytoplasm and in the nucleus were significantly associated with the prognosis of leiomyosarcoma and synovial sarcoma patients in multivariate Cox's regression hazard analyses (adjusted to tumor stage, tumor localization and type of tumor resection). Patients whose tumors expressed survivin in the cytoplasm moderately possessed a 5.7-fold increased risk of tumor-related death (P = 0.004) compared to patients with tumors, that showed a weak expression of survivin (Table 2; Fig. 2A). Expression in the nucleus was again for the patients whose tumors carried a moderate survivin expression associated with a significantly increased risk of tumor-related death (RR = 5.7; P = 0.022; Table 2; Fig. 2B). Next, we studied the possibility of an additive effect of cytoplasmic and nuclear expression of survivin on survival. Patients of group 3 with a moderate or strong survivin staining in the cytoplasm and a moderate survivin expression in the nucleus possessed an additive significantly increased risk of tumor-related death (24.8-fold; P = 0.003; Table 2, Fig. 2C) compared to patients (group1) with a weak expression of survivin both in cytoplasm and nucleus in their tumors. In a Kaplan-Meier analysis patients of group 3 survived on average 29 months whereas patients in group 1 had an average survival time of 73 months but this was not significant because of the limited number of patients in both groups (P = 0.17; data not shown).
Figure 2
Figure 2

Multivariate Cox's regression hazard analysis. Survivin expression in the cytoplasm and/or in nucleus is correlated with a poor prognosis for leiomyosarcoma and synovial sarcoma patients. Survivin expression in the cytoplasm (A) and in the nucleus (B) A: Upper curve: weak expression; 2nd curve: strong expression; 3rd curve: negative expression and lower curve: moderate expression of survivin in the cytoplasm. B: Upper curve: weak expression; 2nd curve: negative expression and lower curve: moderate expression of survivin in the nucleus. Combined expression of survivin in the cytoplasm and in the nucleus (C) C: Upper curve: Survivin expression both in cytoplasm and in nucleus weak (all IRS = 3-4); 2nd upper curve: all other cases and lower curve: Survivin expression in cytoplasm moderate or strong and survivin expression in nucleus moderate (all IRS ≥ 6).

Discussion

Detection of survivin by immunohistochemistry allows distinguishing between survivin expression in the two subcellular pools (cytoplasmic and nuclear). Survivin expression in the cytoplasm could be associated with its control function of cell survival (inhibitor of apoptosis) whereas nuclear staining may rather promote cell proliferation [19]. We investigated both cytoplasmic and nuclear expression of survivin in the soft tissue sarcoma entities leiomyosarcoma and synovial sarcoma. Although, a somewhat higher expression of survivin in synovial sarcomas compared with leiomyosarcomas was detected this difference was not significant. Therefore, we combined tumor samples of both entities for our prognostic evaluations. Both a moderate expression of survivin in the cytoplasm and in the nucleus was correlated with the poorest prognosis of these soft tissue sarcoma patients (RR = 5.7). Remarkably, the patient group with moderate expression of survivin in their tumors includes a higher proportion of retroperitoneal leiomyosarcomas with a poor survival. However, a negative expression of survivin both in the cytoplasm and in the nucleus was, although not significantly, associated with a poor outcome compared with patients whose tumors showed a weak expression of survivin. This finding could be of relevance in planning therapeutic strategies that target survivin. When we combined survivin expression in the cytoplasm and in the nucleus patients whose tumors showed an elevated expression in both compartments carried an additive increased risk of tumor related death (RR = 24.8; P = 0.003) compared to patients with a weak expression of survivin in their tumors. We suggest that survivin expression both in the cytoplasm and in the nucleus should be considered together to evaluate its impact on prognosis.

Recently, the export of nuclear survivin to the cytoplasm could be shown as causal for the survivin-mediated protection against chemo- or radiotherapy-induced apoptosis [23]. Therefore, investigation of survivin expression in different sarcoma entities may have importance for future therapy options. Recently, treatment of rhabdomyosarcoma xenografts with Survivin-shRNA-encoding plasmids showed greater than 70% reduction in growth when compared with control injected tumors [16]. There are several strategies under investigation to target survivin include antisense oligonucleotides, siRNA, ribozymes, immunotherapy and small molecular weight molecules [24]. The translation of these findings to the clinic is currently ongoing with a number of phaseI/II clinical trials including antisense oligonucleotide LY2181308, the low molecular weight molecule inhibitor YM155 and survivin-directed autolougous cytotoxic T lymphocytes [24] The latter strategy, i.e. survivin peptide vaccination w/o different combination therapies has been or is recently applied in different phase I/II clinical trials for advanced melanoma, myeloma, plasma cell neoplasm, pancreatic, colon, cervical, breast, oral cancer and renal cell carcinoma [24–26].

Conclusion

Altogether inhibition of survivin and other stem cell- associated genes [15] in combination with radio-chemotherapy and/or immunotherapy may help to improve sarcoma therapy in the future.

In summary, both cytoplasmic and nuclear expression of survivin detected by immuno-histochemistry is an independent prognostic factor for leiomyosarcoma and synovial sarcoma patients.

Abbreviations

STS: 

soft tissue sarcoma

IRS: 

immunoreactive score

Declarations

Acknowledgements

We would like to thank Mrs. Jana Beer/Institute of Pathology Halle for excellent technical support at immunohistochemical staining. HT and KDS were supported by the Deutsche Krebshilfe (grant number: 107590). Furthermore, HT and MB were supported by the Deutsche Krebshilfe (grant number: 106764) and Wilhelm-Roux-Program of BMBF/NBL3 (FKZ: 14/27, 16/18 and 19/31). This work was associated to the German Sarcoma Study Group KoSar.

Authors’ Affiliations

(1)
Department of Oral and Maxillofacial Plastic Surgery, Martin-Luther-University Halle- Wittenberg, Halle, Germany
(2)
Institute of Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
(3)
Section for Musculoskeletal Tumor Surgery, Center for Musculoskeletal Surgery, Charité - University Medicine, Berlin, Germany
(4)
Department of Radiotherapy, Martin-Luther-University Halle-Wittenberg, Halle, Germany
(5)
Malteser St. Franziskus Hospital gGmbH, Flensburg, Germany
(6)
Department of Pathology, Charité - University Medicine, Berlin, Germany

References

  1. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG: Synovial sarcoma: a retrospective analysis of 271 patients of all ages at a single institution. Cancer. 2004, 101: 627-634. 10.1002/cncr.20386.View ArticlePubMedGoogle Scholar
  2. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW: Analysis of human transcriptomes. Nat Genet. 1999, 23: 387-388. 10.1038/70487.View ArticlePubMedGoogle Scholar
  3. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396: 580-584. 10.1038/25141.View ArticlePubMedGoogle Scholar
  4. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999, 1: 461-466. 10.1038/70242.View ArticlePubMedGoogle Scholar
  5. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL: Human survivin is a kinetochoreassociated passenger protein. J Cell Biol. 2000, 151: 1575-1582. 10.1083/jcb.151.7.1575.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000, 10: 1319-1328. 10.1016/S0960-9822(00)00769-7.View ArticlePubMedGoogle Scholar
  7. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003, 3: 46-54. 10.1038/nrc968.View ArticlePubMedGoogle Scholar
  8. Brabletz S, Schmalhofer O, Brabletz T: Gastrointestinal stem cells in development and cancer. J Pathol. 2009, 217: 307-317. 10.1002/path.2475.View ArticlePubMedGoogle Scholar
  9. Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, Schmidt U, Würl P, Bache M, Schmidt H, Taubert H, Meye A: Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res. 2003, 9: 1098-1104.PubMedGoogle Scholar
  10. Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer. 2005, 114: 509-512. 10.1002/ijc.20768.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR: Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003, 29: 379-382. 10.1053/ejso.2002.1415.View ArticlePubMedGoogle Scholar
  12. Wang W, Luo H, Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol. 2006, 93: 578-584. 10.1002/jso.20507.View ArticlePubMedGoogle Scholar
  13. Clark JC, Dass CR, Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008, 134: 281-297. 10.1007/s00432-007-0330-x.View ArticlePubMedGoogle Scholar
  14. Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C, Rieber EP, Schmidt H, Bache M, Taubert H, Meye A: Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer. 2001, 95: 360-363. 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1.View ArticlePubMedGoogle Scholar
  15. Taubert H, Würl P, Greither T, Kappler M, Bache M, Bartel F, Kehlen A, Lautenschläger C, Harris LC, Kaushal D, Füssel S, Meye A, Böhnke A, Schmidt H, Holzhausen HJ, Hauptmann S: Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene. 2007, 26: 7170-7174. 10.1038/sj.onc.1210530.View ArticlePubMedGoogle Scholar
  16. Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA: Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet. 2006, 43: 119-128. 10.1136/jmg.2005.034686.View ArticlePubMedGoogle Scholar
  17. Tabone-Eglinger S, Bahleda R, Côté JF, Terrier P, Vidaud D, Cayre A, Beauchet A, Théou-Anton N, Terrier-Lacombe MJ, Lemoine A, Penault-Llorca F, Le Cesne A, Emile JF: Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Sarcoma. 2008, 2008: 10.1155/2008/849156. Article ID 849156Google Scholar
  18. Van Unnik JA, Coindre JM, Contesso G, Albus-Lutter CE, Schiodt T, Sylvester R, Thomas D, Bramwell V, Mouridsen HT: Grading of Soft Tissue Sarcomas: Experience of the EORTC Soft and Bone Sarcoma Group. Eur J Cancer. 1993, 29A: 2089-2093. 10.1016/0959-8049(93)90039-I.View ArticlePubMedGoogle Scholar
  19. Wittekind C, Meyer HJ, Bootz F: UICC TNM Klassifikation maligner Tumoren. 2002, Springer-Verlag, Berlin, Heidelberg, New York, 152-156. 6Google Scholar
  20. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J, Vordermark D: Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys. 2006, 66: 1481-1487.View ArticlePubMedGoogle Scholar
  21. Eckert AW, Lautner MH, Taubert H, Schubert J, Bilkenroth U: Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep. 2008, 20: 1381-1385.PubMedGoogle Scholar
  22. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-140.PubMedGoogle Scholar
  23. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovács AF, Stauber RH: Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007, 211: 532-540. 10.1002/path.2134.View ArticlePubMedGoogle Scholar
  24. Ryan BM, O'Donovan N, Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009, 35: 553-562. 10.1016/j.ctrv.2009.05.003.View ArticlePubMedGoogle Scholar
  25. Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T, Sato N: Phase I clinical study of anti-apoptosis protein survivin- derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother. 2009, 58: 1801-1807. 10.1007/s00262-009-0691-x.View ArticlePubMedGoogle Scholar
  26. Kobayashi J, Torigoe T, Hirohashi Y, Idenoue S, Miyazaki A, Yamaguchi A, Hiratsuka H, Sato N: Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin- 2B in oral cancer patients. J Transl Med. 2009, 7: 1-11. 10.1186/1479-5876-7-1.View ArticlePubMedPubMed CentralGoogle Scholar

    27. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/65/prepub

Copyright

© Taubert et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us